Genoptix, Inc. To Announce Third Quarter 2010 Financial Results
CARLSBAD, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, announced today that it expects to report its financial results for the third quarter 2010 after closing of the NASDAQ Global Select Market on Thursday, November 4, 2010.
A conference call hosted by President and CEO, Tina S. Nova, Ph.D., and other members of senior management will take place on the same day at 5:00 p.m. ET ( 2:00 p.m. PT) and will be webcast live on the Genoptix website.
To access the live conference call via phone, dial 800-573-4754 in the U.S. or Canada and 617-224-4325 for international callers. Please specify to the operator that you would like to join the "Genoptix Third Quarter 2010 Earnings Conference Call." The participant code for the call is 96795959. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, November 11, 2010. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 77666858.
The conference call will be webcast live on the Internet and is accessible through the "Investors" section of the Genoptix website at www.genoptix.com, or by accessing the external website, www.fulldisclosure.com. To participate in the webcast, please connect to the Genoptix website several minutes prior to the start time to register, download and install any necessary software that may be required. An online replay is planned to follow shortly after and will be available until Thursday, December 2, 2010.About Genoptix, Inc. Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma, and other forms of cancer. Founded in 1999, Genoptix is a member of the Nasdaq Global Select Market, the S&P SmallCap 600 Index and the Russell 2000 Index and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com. Forward-Looking Statements This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements. SOURCE Genoptix, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV